Perioperative Use of Continuous Glucose Monitoring for Scheduled Cesarean Deliveries (PERUSE)

Perioperative Use of Continuous Glucose Monitoring for Scheduled Cesarean Deliveries (PERUSE): A Pilot Study

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07671599

Acronym

PERUSE

Enrollment

150

Registered

2026-06-26

Start date

2026-09-01

Completion date

2028-05-01

Last updated

2026-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysglycemia

Brief summary

This prospective pilot study is exploratory in nature and is designed to evaluate the validity of continuous glucose monitor (CGM) use for perioperative glucose surveillance during scheduled Cesarean delivery for nondiabetic patients. Primary objective is characterization of perioperative glucose trends during elective Cesarean delivery in patients without diabetes and exploratory analyses will describe perioperative glucose patterns captured by CGM. Secondary objective is to examine rates of and associations with post-operative complications, including surgical site infections.

Interventions

DEVICEContinuous Glucose Monitor

Continuous glucose monitor during perioperative Cesarean delivery

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* singleton pregnancy * no prior diagnosis of diabetes (gestational included) * scheduled term cesarean delivery in Mount Sinai Health System * aged 18-50 years

Exclusion criteria

* preexisting diabetes mellitus * diagnosis of gestational diabetes mellitus (GDM) in the current pregnancy, based on standard prenatal screening * known endocrine disorder affecting glucose metabolism (such as Cushing syndrome, poorly controlled thyroid disorder, etc.) * use of antenatal steroids within the two weeks prior to delivery

Design outcomes

Primary

Measure	Time frame	Description
interstitial glucose from CGM device	from pre-operative appointment through end of postpartum hospital stay, up to ten days	glucose of interstitial fluid as measured by CGM device on participant's arm

Secondary

Measure	Time frame	Description
Number of surgical site infection	Post-op through end of postpartum hospital say, up to ten days.	Diagnosis of surgical site infection as a measure of post-operative complications

Countries

United States

Contacts

CONTACTNicola F Tavella, MPH

nicola.tavella@mssm.edu(212) 241-3888

CONTACTKavya Shivashankar, MD

kavya.shivashankar@mssm.edu(212) 241-5681

PRINCIPAL_INVESTIGATORAngela Bianco, MD

Faculty

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 27, 2026